Shanghai Kaibao Pharmaceutical CO.,Ltd

Short Term Long Term Short Term Comparison Long Term Comparison
  • 300039
  • 1d-1.19%
  • 1w-2.68%
  • 1m-9.80%
  • 1y-20.91%
ATH
  • ATH Price$16.18
  • ATH Date2015-06-15
  • % since ATH-64.16%
  • % to ATH178.98%
ATL
  • ATL Price$3.32
  • ATL Date2010-01-25
  • % from ATL74.44%
  • Last Low Price$3.582
  • Last Low Date2019-01-31
  • % From Last Low61.92%
IPO
  • IPO Price$45.50
  • % Current ROI USD-87.25%
  • ATH Price$16.18
  • % ROI ATH 48,666.13%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="300039"]

Key Data [addtoany]

Current price $5.8
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Today's High/Low $5.94/$5.7
Volume 14,739,779.00
Previous Close $5.87
52 Week High/Low $8.5143/$5.25
Market Cap 6,140,019,712.00
P/E Ratio 22.5769
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $0
Annualized Dividend $0.0102
$5.8
[addtoany]

Shanghai Kaibao Pharmaceutical CO.,Ltd researches, develops, produces, and sells modern Chinese medicines primarily in China. The company’s primary product is Tanreqing injection that clears heat and detoxifies; relieves cough and removes phlegm; and for treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infection.
It also provides Kaibao Chuanxiong capsules; Kaibao Weiyuan tablets; And Kaibao pressure-release sustained release tablets.
In addition, the company offers western medicines in various dosage forms, such as lyophilized powder injection, small volume injection, tablet, capsule, granule, pill, cream, and other dosage forms.
Its western medicines comprise Kaixilai freeze-dried powder, tiopronin sodium, ginseng capsule, and Shanhaidan, alopecia areata, as well as Yuanman brand health win.
The company is also developing Youxinding Capsule for treatment of depressions, which is in phase II clinical study; classic Fangding Guiyou soft capsule that is in phase III clinical study; Shufeng analgesic capsule for the treatment of migraine, which is in phase III clinical study; Huadan Anshen mixture for anti-insomnia that is in phase III clinical study; and Tanzheqing series of products, which is in phase III clinical study. Shanghai Kaibao Pharmaceutical CO.,Ltd was founded in 2000 and is based in Shanghai, China.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity